Sirius Therapeutics

Executive Summary

Sirius Therapeutics is a private, Phase 2 biotechnology company pioneering RNAi-based medicines for chronic diseases. Headquartered in San Diego, the company aims to revolutionize treatment paradigms by harnessing the precision of RNA interference to silence disease-causing genes. With a strong emphasis on innovation and patient-centricity, Sirius is advancing a pipeline of novel therapeutics targeting high unmet needs in metabolic, cardiovascular, and fibrotic disorders. The company's lead program is in Phase 2 clinical development, with early data suggesting promising efficacy and safety profiles. Backed by a seasoned management team and strategic collaborations, Sirius is well-positioned to become a leader in the RNAi space, offering potential first-in-class or best-in-class therapies.

Upcoming Catalysts (preview)

• Q4 2026Phase 2 data readout for lead RNAi candidate60% success
• Q2 2027Partnership or licensing deal for a second-generation pipeline asset40% success
• Q1 2027IND filing for a next-generation RNAi therapy in a new indication50% success